TME Pharma announced positive data from the GLORIA expansion arm in Glioblastoma

CAR-T Digest - August 2020

27 Jun 2023: NOX-A12 / Glioblastoma / TME Pharma: 15 months survival data from GLORIA expansion arm

Phase 1/2 GLORIA study of NOX-A12 + Irradiation in 1L Glioblastoma patients with unmethylated MGMT promoter with a 3-arm expansion group including fully resected patients and combination With Bevacizumab or Pembrolizumab (n = 27)
Results: NOX-A12 + SoC radiotherapy and Bevacizumab (n = 06)
- 83% of glioblastoma patients remain alive after 15 months on study, unchanged from the 14-month survival update
- 15-month mark further surpasses the expected survival in patients resistant to chemotherapy with incomplete surgical tumor removal
- Survival data will improve further as time progresses and patients remain on the study
- As a reference, the expected mOS for patients under the current SoC with chemo-refractory tumors (MGMT unmethylated) and whose tumor remains detectable after surgical intervention is ~10 months
TME Pharma believes that the continued strong performance improves NOX-A12 profile for partnering and eligibility for accelerated regulatory pathways
“Reaching the 15-month survival point with this expansion arm is a significant milestone in our development of NOX-A12 in glioblastoma, and to do so with more than 80 percent of patients still on study represents a fantastic achievement,” said Aram Mangasarian, CEO of TME Pharma